Laboratory monitoring regimens for OPAT
Abstract:
The optimal laboratory monitoring frequency for outpatient parenteral antimicrobial therapy-related adverse events (OPAT-AEs) during cefazolin and ceftriaxone therapy is not well defined. We identified 2.7 OPAT-AEs per 1000 sets of weekly laboratory tests in this population, suggesting that less intensive laboratory monitoring may be safe and reasonable.
Reference:Sunagawa SW, Arduser S, Miller MM, Lyden E, LeMaster M, Cortes-Penfield N, Hankins RJ, Bergman SJ, Alexander BT. Serious Adverse Events and Laboratory Monitoring Regimens for Outpatient Parenteral Antimicrobial Therapy With Cefazolin and Ceftriaxone. Open Forum Infect Dis. 2023 Dec 2;10(12):ofad606. doi: 10.1093/ofid/ofad606. PMID: 38111751; PMCID: PMC10727193.